Overview of Ductal Carcinoma in Situ of the Breast


We review relevant publications on ductal carcinoma in situ of the breast in the past three years and we discuss pattern of outcome lightened by new molecular approach and techniques of radiotherapy.

Share and Cite:

P. Gaye and A. Kassé, "Overview of Ductal Carcinoma in Situ of the Breast," Journal of Cancer Therapy, Vol. 5 No. 2, 2014, pp. 222-224. doi: 10.4236/jct.2014.52028.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] V. L. Ernster, R. Ballard-Barbash, W. E. Barlow, et al., “Detection of Ductal Carcinoma in Situ in Women Undergoing Screening Mammography,” Journal of the National Cancer Institute, Vol. 94, No. 20, 2002, pp. 1546-1554. http://dx.doi.org/10.1093/jnci/94.20.1546
[2] E. Morris and L. Liberman, “Ductal Carcinoma in Situ,” In: E. A. Morris and L. Liberman, Eds., Breast MRI: Diagnosis and Intervention, Springer, Philadelphia, 2004.
[3] J. Richard. L. A. Lee, S. A. Vallow, McLaughlin, K. S. Tzou, S. L. Hines and J. L. Peterson. “Ductal Carcinoma in Situ of the Breast,” International Journal of Surgical Oncology, Vol. 2012, 2012, Article ID 123549. http://dx.doi.org/10.1155/2012/123549
[4] R. Whitfield, J. Kollias, P. de Silva, J. Turner and G. Maddern, “Management of Ductal Carcinoma in Situ according to Van Nuys Prognostic Index in Australia and New Zealand,” ANZ Journal of Surgery, Vol. 82, No. 7-8, 2012, pp. 518-523. http://dx.doi.org/10.1111/j.1445-2197.2012.06133.x
[5] S. F. Shaitelman, J. B. Wilkinson, L. L. Kestin, H. Ye, N. S. Goldstein, A. A. Martinez and F, A. Vicini, “Long Term Outcome in Patients with ductal Carcinoma in Situ Treated with Breast Conserving Therapy: Implications for Optimal Follow up Strategies,” International Journal of Radiation Oncology * Biology * Physics, Vol 83, No. 3, 2012, pp. 305-312.
[6] S. K. Childs, Y.-H. Chen, M. M. Duggan, M. Golshan, S. Pochebit, R. S. Punglia, J. S. Wong and J. R. Bellon. “Impact of Margin Status on Local Recurrence after Mastectomy for Ductal Carcinoma in Situ,” International Journal of Radiation Oncology * Biology * Physics, Vol. 85, No. 4, 2013, pp. E948-E952.
[7] E. Rakovitch, S. A. Narod, S. Nofech-Moses, W. Hanna, D. Thiruchelvam, R. Saskin, C. Taylor, A. Tuck, B. Yougson, N, Miller, S. J. done, S. Sengupta, L. Elavathil, P. A. Jani, M. Bonin, S. Metcalfe and L. Paszat, “Impact of Boost Radiation in the Treatment of Ductal Carcinoma in Situ: A Population-Based Analysis,” International Journal of Radiation Oncology * Biology * Physics, Vol. 86, No. 3, 2013, pp. 491-497. http://dx.doi.org/10.1016/j.ijrobp.2013.02.031
[8] F. N. Aguiar, H. N. Mendes, C. S. Cirqueira, C. E. Bacchi and F. M. Carvalho, “Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ,” Clinics (Sao Paulo), Vol. 68, No. 5, 2013, pp. 638-64. http://dx.doi.org/10.6061/clinics/2013(05)010
[9] R. R. Parikh, B. G. Haffty, D. Lannin and M. S. Moran, “Ductal Carcinoma in Situ With Microinvasion: Prognostic Implications, Long-Term Outcomes, and Role of Axillary Evaluation,” International Journal of Radiation Oncology * Biology * Physics, Vol. 82, No. 1, 2012, pp. 7-13.
[10] B. Fisher, J. Dignam, N. Wolmark, et al., “Tamoxifen in Treatment of Intraductal Breast Cancer: National Surgical Adjuvant Breast and Bowel Project B-24 Randomised Controlled Trial,” Lancet, Vol. 353, No. 9169, 1999, pp. 1993-2000. http://dx.doi.org/10.1016/S0140-6736(99)05036-9
[11] J. Houghton, W. D. George, J. Cuzick, et al., “Radiotherapy and Tamoxifen in Women with Completely Excised Ductal Carcinoma in Situ of the Breast in the UK, Australia, and New Zealand: Randomised Controlled Trial,” Lancet, Vol. 362, No. 9378, 2003, pp. 95-102. http://dx.doi.org/10.1016/S0140-6736(03)13859-7

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.